Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Target Validation, 2011
    The Sigma 1 Receptor as a Target for Disease-modifying Therapies in Parkinson's Disease

    Objective/Rationale: 
    The Sigma-1 receptor (Sig-1R) is a protein involved in the transport of lipids and proteins between organelles within the cell. Impairment of these intracellular trafficking...

  • Target Validation, 2011
    Validation of Dorsal Column Electrical Stimulation as a Target for Parkinson's Disease Therapy

    Objective/Rationale: 
    Direct electrical stimulation of certain areas of the brain is an effective method to treat the motor symptoms of Parkinson’s, but it requires the insertion of electrodes into the...

  • Target Validation, 2011
    Lamp-2a as a Therapeutic Target in Parkinson's Disease

    Objective/Rationale: 
    Multiple pieces of evidence converge on the notion that accumulation of the protein alpha-synuclein is important for Parkinson’s disease (PD) pathogenesis. One of the ways through...

  • Rapid Response Innovation Awards, 2011
    Direct Reprogramming of Cells into Dopamine Neurons

    Objective/Rationale: 
    The availability of dopaminergic neurons for in-depth study or therapeutic replacement approaches has traditionally been limited. We aim to reprogram cells into dopaminergic...

  • Rapid Response Innovation Awards, 2011
    Whole Exome Sequencing in an Amish Parkinson's Disease Pedigree

    Objective/Rationale: 
    Although there is strong evidence to suggest genetics plays a role in Parkinson’s disease, the majority of the genes involved in Parkinson’s disease remain unidentified. We...

  • LRRK2 Target Engagement Ligand, 2011
    Evaluating Novel Small Molecule Inhibitors of LRRK2 to Deliver PET Ligands

    Objective/Rationale: 
    The exciting discovery of activating mutations in the LRRK2 kinase in familial PD patients, coupled with the emergence of kinase inhibitors as a new class of efficacious drugs...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.